
What We're Reading: Ohio's Opioid Rule for Chronic Pain; Rituximab Biosimilar Rejected; VA Nominees Vetted
Ohio proposes safety checkpoints for patients with chronic pain when their painkiller dose is increased; Sandoz's proposed rituximab biosimilar is rejected by the FDA; the White House is vetting 3 potential nominees with stronger political backgrounds for secretary of the Department of Veterans' Affairs.
Ohio Proposes Opioid Rule for Patients With Chronic Pain
Instead of setting limits on prescription opioids, Ohio Governor John Kasich, Republican, is proposing safety checkpoints to re-evaluate patients with chronic pain.
FDA Rejects Rituximab Biosimilar
Sandoz has received a Complete Response Letter (CRL) from the FDA for its proposed rituximab biosimilar. The drug has been approved in Europe, marketed under the brand name Rixathan, and Sandoz hoped to gain approval for the 6 indications of the reference product,
White House Considers 3 Candidates for VA Secretary
After Rear Admiral Ronny Jackson, MD,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.